文献速递其他结缔组织病

romilkimab治疗早期弥漫性皮肤型系统性硬化症:24周随机双盲安慰剂对照II期验证性研究

A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis.
PubMed 文献 · Ann Rheum Dis · 2020-09-22

这项24周随机双盲安慰剂对照II期研究纳入97例早期弥漫性皮肤型系统性硬化症患者,评估romilkimab(抗IL-4/IL-13双特异性抗体)200mg皮下每周一次对改良Rodnan皮肤评分(mRSS)的影响。结果显示romilkimab组mRSS较基线下降优于安慰剂组,组间差异有统计学意义,安全性事件两组均衡,但结论需更长疗程III期研究确认临床相关性。

要点

  • romilkimab组24周mRSS最小二乘均值变化为-4.76,安慰剂组为-2.45,组间差异-2.31(90%CI -4.32至-0.31;p=0.0291,单侧)。
  • 治疗中出现的不良事件两组均衡(安慰剂84% vs romilkimab 80%),多为轻至中度,停药率低。
  • romilkimab未观察到心脏安全性信号,但研究结论需更长、更全面的III期研究确认临床相关性。

核心结论

  • romilkimab在早期弥漫性皮肤型系统性硬化症中显示出对皮肤改变有统计学意义的效应,需更长更全面的III期研究确认临床相关性。

研究设计与样本

  • 随机、双盲、安慰剂对照、24周II期验证性研究,纳入97例年龄≥18岁的弥漫性皮肤型系统性硬化症患者,按1:1随机接受皮下romilkimab 200mg或安慰剂每周一次,可联用免疫抑制背景治疗。

主要发现

  • romilkimab组mRSS从基线至第24周的最小二乘均值(SE)变化为-4.76(0.86),安慰剂组为-2.45(0.85),组间差异为-2.31(1.21)(90%CI -4.32至-0.31;p=0.0291,单侧)。
  • 治疗中出现的不良事件在安慰剂组(n=41;84%)与romilkimab组(n=40;80%)之间均衡,多为轻至中度,总体停药3例。
  • 共发生2例死亡(romilkimab组1例硬皮病肾危象,安慰剂组1例心肌病),均被认为与治疗无关;安慰剂组2例患者发生心血管治疗中出现严重不良事件(1例心力衰竭,1例心肌病),romilkimab未观察到心脏安全性信号。

关键数值与推荐

  • 主要终点为改良Rodnan皮肤评分(mRSS)从基线至第24周的变化。
  • romilkimab组mRSS最小二乘均值(SE)变化为-4.76(0.86),安慰剂组为-2.45(0.85)。
  • 组间最小二乘均值(SE)差异为-2.31(1.21)(90%CI -4.32至-0.31;p=0.0291,单侧)。

临床怎么用

  • romilkimab可能改善早期弥漫性皮肤型系统性硬化症患者的皮肤厚度,但当前证据尚不足以支持临床常规使用,需等待III期研究结果。

局限性

  • 研究为24周II期验证性研究,样本量97例,结论需更长、更全面的III期研究确认临床相关性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Recent advances in systemic sclerosis (SSc) show that it involves a T-helper type-2-oriented immune response with interleukin (IL)-4 and IL-13. Romilkimab is an engineered, humanised, bispecific immunoglobulin-G4 antibody that binds and neutralises IL-4/IL-13 making it ideal for exploration in fibrosis. METHODS: Patients aged ≥18 years diagnosed with diffuse cutaneous SSc (dcSSc), and with or without immunosuppressive background therapy, were randomised (1:1) to subcutaneous romilkimab 200 mg or placebo one time per week for 24 weeks in this double-blind, proof-of-concept, phase II study. The primary endpoint was change in modified Rodnan skin score (mRSS) from baseline to week 24. RESULTS: Ninety-seven patients were randomised to romilkimab (n=48) or placebo (n=49) for 24 weeks. Least-squares mean (SE) change in mRSS was -4.76 (0.86) for romilkimab versus -2.45 (0.85) for placebo yielding a mean (SE) (90% CI) difference of -2.31 (1.21) (-4.32 to -0.31; p=0.0291, one-sided). Treatment-emergent AEs were balanced between placebo (n=41; 84%) and romilkimab (n=40; 80%). Most were mild-to-moderate and discontinuations were low (three overall). There were two deaths (one scleroderma renal crisis (romilkimab) and one cardiomyopathy (placebo)), neither were considered treatment related. Two patients in the placebo group had a cardiovascular treatment-emergent SAE (one cardiac failure, one cardiomyopathy), but there were no cardiac safety signals with romilkimab. CONCLUSION: This study demonstrated significant effects on skin changes with romilkimab in early dcSSc that require confirmation with a longer and more comprehensive phase III study to determine clinical relevance. TRIAL REGISTRATION NUMBER: NCT02921971.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Allanore Y, Wung P, Soubrane C, et al. A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2020. PMID: 32963047. doi:10.1136/annrheumdis-2020-218447

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。